PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1100103
PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1100103
The North America medication-assisted treatment (MAT) market is projected to register a substantial CAGR of 9.7% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2019, the base year of calculation is 2021, and the forecast period is 2022 to 2029.
North America Medication-Assisted Treatment (MAT) Market, By Type (Medication and Therapy), Products (Buprenorphine and Naloxone, Naltrexone, Buprenorphine, Methadone, Naloxone, Disulfiram, and Acamprosate), Drug Type (Generics and Branded), Dosage Form (Immediate Release and Extended Release), Route of Administration (Oral, Parenteral, and Others), Population Type (Adults and Teenage), End User (Rehabilitation Clinics, Hospitals, Specialty Centres, Homecare, and Others) Distribution Channel (Hospital Pharmacy, Direct Tender, Retail Pharmacy, Online Pharmacy, and Others), Country (U.S., Canada, and Mexico) Industry Trends and Forecast to 2029
The rise in the population receiving medication-assisted treatment (MAT)
Availability of reimbursement for medication-assisted treatment (MAT)
Indivior PLC
Orexo US Inc (a subsidiary of Orexo AB)
Recovery Centers of America
Alkermes
Sun Pharmaceutical Industries Ltd.
Purdue Pharma L.P.
Taj Pharmaceuticals Limited
Lannett
Hikma Pharmaceuticals PLC
Pfizer Inc.
Pinnacle Treatment Center
American Addiction Centers
Adamis Pharmaceuticals Corporation
Glenmark Pharmaceutical Inc.
Viatris Inc.
Mallinckrodt
Alvogen
VistaPharm, Inc.
Teva Pharmaceutical Industries Ltd.
Dr. Reddy's Laboratories Ltd.
Amneal Pharmaceuticals LLC.
Titan Pharmaceuticals, Inc.